Full Text

Turn on search term navigation

© 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The study reports synthesize of novel Schiff base ligand decorated with pyrazolone moiety using 4-Aminoantipyrine phosphate and 5-Bromosalicylaldehyde. Structural characterization of the synthesized pyrazolone moiety was carried out using 1H-NMR, Mass Spectroscopy, elemental analysis with EDAX, UV-Vis spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR) and single crystal X-Ray diffraction. Novel Schiff base ligand was tested for its bioefficacy, which showed having the properties like antimicrobial against Escherichia coli (MTCC433), Staphylococcus aureus (MTCC3160), antifungal against Aspergillus niger (MTCC2208) Candida albicans (MTCC3160), antioxidant and anti-inflammatory activities. Cytotoxicity study was carried out on Hep G2 cell lines and Vero cell lines, which revealed the anticancer activity of the Schiff base ligand. Molecular docking interaction of ligand towards enzymes like DNA gyrase of E.coli, S. aureus showed good binding energy. The optimum synthesizing temperature of Schiff base ligand was found to be at 30°C, and the synthesised ligand was found to be biologically effective.

Details

Title
Synthesis and the Study of Bioefficacy of Schiff Base Ligand Decorated by Pyrazolone Moiety
Author
Rajasekaran, Anuradha; Abraham, Selvan; Sasikala Mohanasundaram; Gurusamy, Pirakathiswaran
Pages
244-253
Publication year
2020
Publication date
2020
Publisher
Oriental Scientific Publishing Company
ISSN
0970020X
e-ISSN
22315039
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2807959052
Copyright
© 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.